Overview

Study Evaluating the Efficacy of DVS-233 in Fibromyalgia

Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if DVS-233 is safe and effective in the treatment of pain and other symptoms of fibromyalgia syndrome.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer